Back to today’s briefing

Story perspectives

Novo Nordisk Launches Oral Wegovy in Germany, Priced €170–280

9/1/2026

29 5

Summary

Story summary

Novo Nordisk launched the oral Wegovy weight-loss pill in Germany, the EU’s first market.
German regulators priced the package at €170-280.
Executives said the pill captures about 90% of the oral obesity market.
Over 5 million prescriptions were filled, with weekly volumes near 265,000 by mid-July 2026.
Second-quarter 2026 net sales rose 7% at constant currency, prompting a full-year guidance increase.

1 of 1

Story summary

Novo Nordisk launched the oral Wegovy weight-loss pill in Germany, the EU’s first market.
German regulators priced the package at €170-280.
Executives said the pill captures about 90% of the oral obesity market.
Over 5 million prescriptions were filled, with weekly volumes near 265,000 by mid-July 2026.
Second-quarter 2026 net sales rose 7% at constant currency, prompting a full-year guidance increase.